MIRA
MIRA Pharmaceuticals, Inc. (NASDAQ)
Healthcare — Drug Manufacturers - General
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.
Price History
Fundamentals
| Market Cap | $39.81M |
| P/E Ratio (TTM) | - |
| Forward P/E | -2.31 |
| EPS (TTM) | $-1.27 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -184.32% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 45.0 |
| Beta | 1.44 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $2.45 |
| 52-Week Low | $0.90 |
| 50-Day Avg | $1.00 |
| 200-Day Avg | $1.25 |
| Avg Volume | 108.0K |
| Volume | 25.2K |
Performance Analysis
NEUTRALMIRA presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:20 UTC
Back to Screener Export Report